Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 336

1.

Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks.

Soni A, Li F, Wang Y, Grabos M, Krieger LM, Chaudhary S, Hasan MSM, Ahmed M, Coleman CN, Teicher BA, Piekarz RL, Wang D, Iliakis GE.

Mol Cancer Ther. 2018 Jul 3. doi: 10.1158/1535-7163.MCT-17-0836. [Epub ahead of print]

PMID:
29970481
2.

Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.

Teicher BA, Silvers T, Selby M, Delosh R, Laudeman J, Ogle C, Reinhart R, Parchment R, Krushkal J, Sonkin D, Rubinstein L, Morris J, Evans D.

Cancer Med. 2017 Aug;6(8):1952-1964. doi: 10.1002/cam4.1131. Epub 2017 Aug 1.

3.

3D Models of the NCI60 Cell Lines for Screening Oncology Compounds.

Selby M, Delosh R, Laudeman J, Ogle C, Reinhart R, Silvers T, Lawrence S, Kinders R, Parchment R, Teicher BA, Evans DM.

SLAS Discov. 2017 Jun;22(5):473-483. doi: 10.1177/2472555217697434. Epub 2017 Mar 13.

PMID:
28288283
4.

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.

Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell SN, Poirier JT, Rudin CM.

Clin Cancer Res. 2017 Jan 15;23(2):523-535. doi: 10.1158/1078-0432.CCR-16-1040. Epub 2016 Jul 20.

5.

Antibody-drug conjugates for cancer therapy.

Thomas A, Teicher BA, Hassan R.

Lancet Oncol. 2016 Jun;17(6):e254-e262. doi: 10.1016/S1470-2045(16)30030-4. Review.

PMID:
27299281
6.

Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.

Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Connelly J, Harris E, Fer N, Sonkin D, Kaur G, Monks A, Malik S, Morris J, Teicher BA.

J Natl Cancer Inst. 2016 May 31;108(10). doi: 10.1093/jnci/djw122. Print 2016 Oct.

PMID:
27247353
7.

Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology.

LeBlanc AK, Breen M, Choyke P, Dewhirst M, Fan TM, Gustafson DL, Helman LJ, Kastan MB, Knapp DW, Levin WJ, London C, Mason N, Mazcko C, Olson PN, Page R, Teicher BA, Thamm DH, Trent JM, Vail DM, Khanna C.

Sci Transl Med. 2016 Feb 3;8(324):324ps5. doi: 10.1126/scitranslmed.aaf0746. Review. No abstract available.

PMID:
26843188
8.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30. Review. No abstract available.

9.

Bromodomain and hedgehog pathway targets in small cell lung cancer.

Kaur G, Reinhart RA, Monks A, Evans D, Morris J, Polley E, Teicher BA.

Cancer Lett. 2016 Feb 28;371(2):225-39. doi: 10.1016/j.canlet.2015.12.001. Epub 2015 Dec 10.

10.

Comprehensive characterization of the Published Kinase Inhibitor Set.

Elkins JM, Fedele V, Szklarz M, Abdul Azeez KR, Salah E, Mikolajczyk J, Romanov S, Sepetov N, Huang XP, Roth BL, Al Haj Zen A, Fourches D, Muratov E, Tropsha A, Morris J, Teicher BA, Kunkel M, Polley E, Lackey KE, Atkinson FL, Overington JP, Bamborough P, Müller S, Price DJ, Willson TM, Drewry DH, Knapp S, Zuercher WJ.

Nat Biotechnol. 2016 Jan;34(1):95-103. doi: 10.1038/nbt.3374. Epub 2015 Oct 26.

PMID:
26501955
11.

Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression.

Teicher BA, Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Connelly J, Harris E, Monks A, Morris J.

Mol Cancer Ther. 2015 Nov;14(11):2452-62. doi: 10.1158/1535-7163.MCT-15-0074. Epub 2015 Sep 8.

12.

Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies.

Rouleau C, Gianolio DA, Smale R, Roth SD, Krumbholz R, Harper J, Munroe KJ, Green TL, Horten BC, Schmid SM, Teicher BA.

Mol Cancer Ther. 2015 Sep;14(9):2081-9. doi: 10.1158/1535-7163.MCT-15-0312. Epub 2015 Jul 16.

13.

What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?

Esteva FJ, Miller KD, Teicher BA.

Am Soc Clin Oncol Educ Book. 2015:e117-25. doi: 10.14694/EdBook_AM.2015.35.e117.

14.

Proteasome inhibitors.

Teicher BA, Tomaszewski JE.

Biochem Pharmacol. 2015 Jul 1;96(1):1-9. doi: 10.1016/j.bcp.2015.04.008. Epub 2015 Apr 29.

15.

CCR 20th anniversary commentary: In the beginning, there was PS-341.

Teicher BA, Anderson KC.

Clin Cancer Res. 2015 Mar 1;21(5):939-41. doi: 10.1158/1078-0432.CCR-14-2549.

16.

Combining targeted agents with modern radiotherapy in soft tissue sarcomas.

Wong P, Houghton P, Kirsch DG, Finkelstein SE, Monjazeb AM, Xu-Welliver M, Dicker AP, Ahmed M, Vikram B, Teicher BA, Coleman CN, Machtay M, Curran WJ, Wang D.

J Natl Cancer Inst. 2014 Oct 18;106(11). pii: dju329. doi: 10.1093/jnci/dju329. Print 2014 Nov. Review.

17.

Antibody drug conjugates.

Teicher BA.

Curr Opin Oncol. 2014 Sep;26(5):476-83. doi: 10.1097/CCO.0000000000000108. Review.

PMID:
25024051
18.

Toward a drug development path that targets metastatic progression in osteosarcoma.

Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, Weigel B, Randall L, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Smith M, Uren A, Patel SR, Trent J, Savage SA, Mirabello L, Reinke D, Barkaukas DA, Krailo M, Bernstein M.

Clin Cancer Res. 2014 Aug 15;20(16):4200-9. doi: 10.1158/1078-0432.CCR-13-2574. Epub 2014 May 6.

19.

Bioenergetic properties of human sarcoma cells help define sensitivity to metabolic inhibitors.

Issaq SH, Teicher BA, Monks A.

Cell Cycle. 2014;13(7):1152-61. doi: 10.4161/cc.28010. Epub 2014 Feb 10.

20.

Targets in small cell lung cancer.

Teicher BA.

Biochem Pharmacol. 2014 Jan 15;87(2):211-9. doi: 10.1016/j.bcp.2013.09.014. Epub 2013 Sep 30. Review.

21.

Perspective: Opportunities in recalcitrant, rare and neglected tumors.

Teicher BA.

Oncol Rep. 2013 Sep;30(3):1030-4. doi: 10.3892/or.2013.2581. Epub 2013 Jul 2.

22.

Analyses of the combination of 6-MP and dasatinib in cell culture.

Kaur G, Behrsing H, Parchment RE, Millin MD, Teicher BA.

Int J Oncol. 2013 Jul;43(1):13-22. doi: 10.3892/ijo.2013.1930. Epub 2013 May 2.

23.

The promise of antibody-drug conjugates.

Teicher BA, Doroshow JH.

N Engl J Med. 2012 Nov 8;367(19):1847-8. doi: 10.1056/NEJMe1211736. No abstract available.

PMID:
23134386
24.

Targeting cancer metabolism.

Teicher BA, Linehan WM, Helman LJ.

Clin Cancer Res. 2012 Oct 15;18(20):5537-45. doi: 10.1158/1078-0432.CCR-12-2587.

25.

Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.

Gianolio DA, Rouleau C, Bauta WE, Lovett D, Cantrell WR Jr, Recio A 3rd, Wolstenholme-Hogg P, Busch M, Pan P, Stefano JE, Kramer HM, Goebel J, Krumbholz RD, Roth S, Schmid SM, Teicher BA.

Cancer Chemother Pharmacol. 2012 Sep;70(3):439-49. doi: 10.1007/s00280-012-1925-8. Epub 2012 Jul 22.

PMID:
22821053
26.

Endosialin expression in side populations in human sarcoma cell lines.

Rouleau C, Sancho J, Campos-Rivera J, Teicher BA.

Oncol Lett. 2012 Feb;3(2):325-329. Epub 2011 Nov 14.

27.

Expression of TMPRSS4 in non-small cell lung cancer and its modulation by hypoxia.

Nguyen TH, Weber W, Havari E, Connors T, Bagley RG, McLaren R, Nambiar PR, Madden SL, Teicher BA, Roberts B, Kaplan J, Shankara S.

Int J Oncol. 2012 Sep;41(3):829-38. doi: 10.3892/ijo.2012.1513. Epub 2012 Jun 12.

28.

Searching for molecular targets in sarcoma.

Teicher BA.

Biochem Pharmacol. 2012 Jul 1;84(1):1-10. doi: 10.1016/j.bcp.2012.02.009. Epub 2012 Feb 22.

PMID:
22387046
29.

Human choriocarcinomas: placental growth factor-dependent preclinical tumor models.

Bagley RG, Ren Y, Kurtzberg L, Weber W, Bangari D, Brondyk W, Teicher BA.

Int J Oncol. 2012 Feb;40(2):479-86. doi: 10.3892/ijo.2011.1257. Epub 2011 Nov 10.

PMID:
22075622
30.

Antibody conjugate therapeutics: challenges and potential.

Teicher BA, Chari RV.

Clin Cancer Res. 2011 Oct 15;17(20):6389-97. doi: 10.1158/1078-0432.CCR-11-1417.

31.

TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence.

Zhang Q, Chen L, Helfand BT, Jang TL, Sharma V, Kozlowski J, Kuzel TM, Zhu LJ, Yang XJ, Javonovic B, Guo Y, Lonning S, Harper J, Teicher BA, Brendler C, Yu N, Catalona WJ, Lee C.

PLoS One. 2011;6(9):e25168. doi: 10.1371/journal.pone.0025168. Epub 2011 Sep 30.

32.

Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy.

Bagley RG, Rouleau C, Weber W, Mehraein K, Smale R, Curiel M, Callahan M, Roy A, Boutin P, St Martin T, Nacht M, Teicher BA.

Microvasc Res. 2011 Nov;82(3):253-62. doi: 10.1016/j.mvr.2011.09.004. Epub 2011 Sep 17.

PMID:
21958527
33.

Endosialin: a novel malignant cell therapeutic target for neuroblastoma.

Rouleau C, Smale R, Sancho J, Fu YS, Kurtzberg L, Weber W, Kruger A, Jones C, Roth S, Bormann C, Dunham S, Krumbholz R, Curiel M, Wallar G, Mascarello J, Campos-Rivera J, Horten B, Schmid S, Miller G, Teicher BA.

Int J Oncol. 2011 Oct;39(4):841-51. doi: 10.3892/ijo.2011.1091. Epub 2011 Jun 20.

PMID:
21701770
34.

Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.

Sooryakumar D, Dexheimer TS, Teicher BA, Pommier Y.

Mol Cancer Ther. 2011 Aug;10(8):1490-9. doi: 10.1158/1535-7163.MCT-10-1043. Epub 2011 Jun 2.

35.

Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

Houghton PJ, Lock R, Carol H, Morton CL, Gorlick R, Anders Kolb E, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Zhang MX, Madden SL, Teicher BA, Smith MA.

Pediatr Blood Cancer. 2012 Feb;58(2):200-9. doi: 10.1002/pbc.23016. Epub 2011 May 5.

36.

Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling.

Rouleau C, Smale R, Fu YS, Hui G, Wang F, Hutto E, Fogle R, Jones CM, Krumbholz R, Roth S, Curiel M, Ren Y, Bagley RG, Wallar G, Miller G, Schmid S, Horten B, Teicher BA.

Int J Oncol. 2011 Jul;39(1):73-89. doi: 10.3892/ijo.2011.1020. Epub 2011 Apr 29.

PMID:
21537839
37.

Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells.

Bagley RG, Kurtzberg L, Rouleau C, Yao M, Teicher BA.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1537-46. doi: 10.1007/s00280-011-1658-0. Epub 2011 Apr 28.

PMID:
21526352
38.

Characteristics of human Ewing/PNET sarcoma models.

Teicher BA, Bagley RG, Rouleau C, Kruger A, Ren Y, Kurtzberg L.

Ann Saudi Med. 2011 Mar-Apr;31(2):174-82. doi: 10.4103/0256-4947.78206. Review.

39.

Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment.

Kurtzberg LS, Roth S, Krumbholz R, Crawford J, Bormann C, Dunham S, Yao M, Rouleau C, Bagley RG, Yu XJ, Wang F, Schmid SM, Lavoie EJ, Teicher BA.

Clin Cancer Res. 2011 May 1;17(9):2777-87. doi: 10.1158/1078-0432.CCR-10-0542. Epub 2011 Mar 17.

40.

Placental growth factor upregulation is a host response to antiangiogenic therapy.

Bagley RG, Ren Y, Weber W, Yao M, Kurtzberg L, Pinckney J, Bangari D, Nguyen C, Brondyk W, Kaplan J, Teicher BA.

Clin Cancer Res. 2011 Mar 1;17(5):976-88. doi: 10.1158/1078-0432.CCR-10-2687. Epub 2011 Feb 22.

41.

sFLT01: a novel fusion protein with antiangiogenic activity.

Bagley RG, Kurtzberg L, Weber W, Nguyen TH, Roth S, Krumbholz R, Yao M, Richards B, Zhang M, Pechan P, Schmid S, Scaria A, Kaplan J, Teicher BA.

Mol Cancer Ther. 2011 Mar;10(3):404-15. doi: 10.1158/1535-7163.MCT-10-0813. Epub 2011 Jan 20.

42.

The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function.

Chai L, McLaren RP, Byrne A, Chuang WL, Huang Y, Dufault MR, Pacheco J, Madhiwalla S, Zhang X, Zhang M, Teicher BA, Carter K, Cheng SH, Leonard JP, Xiang Y, Vasconcelles M, Goldberg MA, Copeland DP, Klinger KW, Lillie J, Madden SL, Jiang YA.

Int J Oncol. 2011 Mar;38(3):701-11. doi: 10.3892/ijo.2010.888. Epub 2010 Dec 24.

PMID:
21186402
43.

Antiangiogenic agents and targets: A perspective.

Teicher BA.

Biochem Pharmacol. 2011 Jan 1;81(1):6-12. doi: 10.1016/j.bcp.2010.09.023. Epub 2010 Oct 12.

PMID:
20920481
44.

Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs.

Teicher BA.

Curr Opin Pharmacol. 2010 Aug;10(4):397-404. doi: 10.1016/j.coph.2010.04.014. Epub 2010 May 22. Review.

PMID:
20547104
45.

CXCL12 (SDF-1)/CXCR4 pathway in cancer.

Teicher BA, Fricker SP.

Clin Cancer Res. 2010 Jun 1;16(11):2927-31. doi: 10.1158/1078-0432.CCR-09-2329. Epub 2010 May 18. Review.

46.

Antibody-drug conjugate targets.

Teicher BA.

Curr Cancer Drug Targets. 2009 Dec;9(8):982-1004. Review.

PMID:
20025606
47.

Human tumor xenografts and mouse models of human tumors: re-discovering the models.

Teicher BA.

Expert Opin Drug Discov. 2009 Dec;4(12):1295-305. doi: 10.1517/17460440903380430. Epub 2009 Nov 7.

PMID:
23480467
48.

Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence.

Byrne A, McLaren RP, Mason P, Chai L, Dufault MR, Huang Y, Liang B, Gans JD, Zhang M, Carter K, Gladysheva TB, Teicher BA, Biemann HP, Booker M, Goldberg MA, Klinger KW, Lillie J, Madden SL, Jiang Y.

Exp Cell Res. 2010 Jan 15;316(2):258-71. doi: 10.1016/j.yexcr.2009.08.018. Epub 2009 Sep 2.

PMID:
19732767
49.

Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008.

Okunieff P, Kachnic LA, Constine LS, Fuller CD, Gaspar LE, Hayes DF, Hooks J, Ling C, Meyskens FL Jr, Philip PA, Raben D, Smalley SR, Swanson GP, Teicher BA, Thomas CR Jr, Vikram B, Zelefsky MJ, Baker LH.

Clin Cancer Res. 2009 Sep 15;15(18):5663-70. doi: 10.1158/1078-0432.CCR-09-0357. Epub 2009 Sep 1.

50.

Flipping the wound that doesn't heal: the upside of coagulation in cancer.

Teicher BA.

Blood. 2009 May 14;113(20):4827-8. doi: 10.1182/blood-2009-03-207316. No abstract available.

Supplemental Content

Loading ...
Support Center